Sharon Mates, Intra-Cellular Therapies CEO

In­tra-Cel­lu­lar on track for an­oth­er Caply­ta la­bel ex­pan­sion af­ter pos­i­tive Ph3 de­pres­sion da­ta

In­tra-Cel­lu­lar Ther­a­pies’ Caply­ta sig­nif­i­cant­ly im­proved symp­toms in a late-stage ma­jor de­pres­sive dis­or­der tri­al, mark­ing a step in the drug’s jour­ney to be­com­ing a pipeline-in-a-pill. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.